Azenta Life Sciences Partners with Frenova, a Division of Fresenius Medical Care, and Nephronomics to Advance Genomic Research in Nephrology

BURLINGTON, Mass., July 31, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that it has entered a collaboration with Frenova, a division of Fresenius Medical Care, and Nephronomics, a Renal Precision Medicine company, to begin genomic sequencing and data generation for Frenova's transformative MyReason® genomics research program. This strategic collaboration aims to leverage cutting-edge technologies to enhance the understanding of cardio-kidney-metabolic diseases and drive advancements in precision medicine for patients worldwide.

Read more at prnewswire.com